Abbott launches generic epilepsy drug into overcrowded Argentina market

Abbott last week launched its antiepileptic medicine Anacet (lacosamide), a generic version of UCB’s Vimpat, to the Argentina market. The oral drug is indicated as an adjuvant therapy against partial-onset seizures with or without secondary generalization in teenage and adult patients with epilepsy.

The exact way in which lacosamide works is still unclear, but it seems to reduce the activity of sodium channels that allow electrical impulses to be transmitted between nerve cells, and it is also thought to be involved in the development of nerve cells that have been damaged.

GBI analysis reveals that, within Latin America, Anacet is registered only in Argentina, where it will compete with UCB’s originator drug and three generics. This coexistence between Vimpat and generic products also occurs in Brazil, Chile, Colombia, and Mexico, while the Ecuador and Peru markets are dominated by generics.


Related news
The Center for Drug Evaluation (CDE) website shows that Novartis’s siponimod tablets, UCB’s lacosamide syrup and Jiangxi Qingfeng Pharmaceutical Co., Ltd’s lacosamide injection were all granted priority review and approval status on May 7.
Belgium-based UCB has handed over China market promotion rights to its Niferex (iron polysaccharide complex capsules) to Shanghai-based Nuance Biotech Inc., according to Mrclub, a local media platform.
A notice from the National Medical Products Administration (NMPA)'s Center for Drug Evaluation reveals that eight products filed for marketing approval have been granted priority review status.
Belgium-based UCB S.A.'s lacosamide tablets, an anti-epilepsy therapy, was reported by local media to have received marketing approval from China’s National Medical Products Administration (NMPA).
Belgium-based UCB revealed that the firm’s Parkinson’s disease therapy Neupro (rotigotine) launched to market in China, with a first prescription issued on October 17.
  • 1541400213271
  • China
  • Drug
Recent news
Zulema Tomás Gonzáles, head of Peru’s Ministry of Health (MINSA), this week announced that she will pressure President Martín Vizcarra to approve through emergency decrees two draft laws aimed at improving health access.
Bayer Consumer Health opened its first Asia-Pacific R&D center, located in Qidong, Jiangsu, China.
Guillaume Corpart, managing director of hospital statistics firm Global Health Intelligence, said during an interview with the Mexico Health Review that recent changes in Mexico’s public sector are putting pressure on drug and medical supplies providers.
Shenzhen-based Ionova Life Science Co., Ltd announced a successful RMB 126 million (USD 17.8 million) in a Series A financing round, led by Lilly Asia Ventures, with DYEE Capital participating.
Swiss major Novartis and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed a memorandum of understanding (MoU) to cooperate in research and development (R&D) and education projects to combat neglected diseases such as Hansen's disease (HD), Chagas disease, malaria, and sickle cell disease.
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP) is moving to take a sizeable stake in US-headquartered biotech OncoSec Medical Inc. An agreement has been reached for CGP to acquire 44.2% of OncoSec for USD 25 million, subject to shareholder approval, with an option to fully buy out the company within 12 months.
  • 1571120805603
  • China
The Implementation Plan for the “Two Invoices” System in Public Medical Institutions Drug Procurement” was jointly released by several ministries in Shandong, led by the Health Commission bureau, as well as the Development and Reform Commission, the Healthcare Security Administration, and others.
Analytics Snapshot

Analytics Snapshot